Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty
Becky J. Fredrickson(Baylor College of Medicine), Larry V. McIntire(Freeman Health System), Mark B. Effron(Eli Lilly (United States)), Neal S. Kleiman(Houston Methodist), Mary Ann Mascelli(Unknown), Kelly Maresh(Eli Lilly (United States)), Nancy A. Turner(Baylor College of Medicine), Nikki Graziadei(Eli Lilly (United States))
Cited by 42
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions
|Blood|2002|853
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Intravenous Platelet Blockade with Cangrelor during PCI
|New England Journal of Medicine|2009|643